Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer
Objective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer. Methods A total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclit...
Main Authors: | MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-09-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0038 |
Similar Items
-
Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
by: Hongming Wang, et al.
Published: (2023-03-01) -
Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
by: Xiguang Liu, et al.
Published: (2022-11-01) -
Postoperative Adjuvant Chemotherapy Improved the Prognosis in Locally Advanced Cervical Cancer Patients With Optimal Response to Neoadjuvant Chemotherapy
by: Xiaojie Feng, et al.
Published: (2020-12-01) -
A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study
by: Tian X, et al.
Published: (2021-11-01) -
Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
by: Shao Feng, et al.
Published: (2022-03-01)